An open-label, multicentre, rollover study to evaluate safety and antineoplastic activity of OATD-02 in patients with selected advances and/or metastatic solid tumours who completed the first-in-human study OATD-02-C-01
Latest Information Update: 10 Oct 2025
At a glance
- Drugs OATD-02 (Primary)
- Indications Colorectal cancer; Ovarian cancer; Pancreatic cancer; Renal cell carcinoma; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Acronyms OATD-02-C-02
- Sponsors Molecure
Most Recent Events
- 16 Sep 2025 New trial record